ARDX: Flat Base detected on 13 Apr 2026
All prices, scores, and news on this page reflect data available before market open on .
Overall Score
78
of 100
Good
Win Probability
67%
Moderate
Reward / Risk
0.3
: 1
$0.03 reward
$-0.11 risk
Current Setup
ARDX is forming a flat base consolidation with structure score 13.0/15 and breakout score 12.0/13, at $6.18 near key resistance of $6.28 and support at $5.11. Volume ratio of 1.03 and recent two-week gain of 8.61% signal accumulation phase. RSI at 55.45 sits neutral in neither overbought nor oversold territory. The stock trades at +92.52% of its 52-week low and -26.43% off 52-week high of $8.40, suggesting oversold recovery potential. Overall pattern quality score of 78/98 with 66.84% win probability indicates moderate-to-good setup strength despite healthcare sector headwinds.
Stock Context
ARDX reported full-year 2025 revenue of $407.3 million with IBSRELA delivery of $274.2 million, up 73% over 2024, and issued 2026 guidance of $410–$430 million IBSRELA revenue (≥50% growth). In February 2026, HC Wainwright lifted FY2026 EPS estimates to $0.18 from $0.12, maintaining a 'Buy' rating with $18.00 price target. Wedbush raised price target to $19.00 with 'outperform' rating; Piper Sandler upgraded from 'neutral' to 'overweight' and raised target to $16.00. Ardelyx announced new patents extending protection to 2042 on tenapanor franchise. However, widening net loss and ongoing reimbursement uncertainty around XPHOZAH remain central risks, causing the recent pullback and creating the setup now.
What to Expect
A successful breakout from this flat base would move price above $6.28 resistance toward conservative target of $6.45, representing a modest 4.4% measured move. Volume must expand above the 3.4M daily average on breakout confirmation. Invalidation occurs if price closes below key support at $5.11, which would negate the setup. With 66.84% historical win probability on this pattern type, the risk-reward structure is modest—suitable for defined-risk entries with stops at $5.11 and targets at $6.45–$6.60.
Risk Factors
Ardelyx must execute on IBSRELA growth guidance while absorbing higher R&D and SG&A from Phase 3 ACCEL trial in chronic idiopathic constipation, delaying near-term profitability. Reimbursement setbacks and concentrated product risk—particularly Medicare coverage shifts for XPHOZAH—could disrupt margin expansion. The healthcare sector regime is bearish (0.18 score) while overall market is bullish, creating cross-current headwinds; beta of 0.55 limits downside protection. Next earnings date is estimated April 30, 2026, creating near-term catalyst risk if guidance misses. No overbought RSI concern (55.45), but elevated volatility at 46.78% (20-day) signals event risk. Investor frustration persists around elevated SG&A spending without visible operating leverage.
Sources:
Ardelyx (ARDX) Is Down 16.3% After Issuing Higher 2026 Product Revenue Guidance and Patent Update - Simply Wall St News
·
Investors & Media | Ardelyx
·
Ardelyx: IBSRELA Momentum Drives Opportunity (NASDAQ:ARDX) | Seeking Alpha
·
Is Ardelyx’s 2026 IBSRELA Outlook Altering The Investment Case For Ardelyx (ARDX)? - Simply Wall St News
·
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook | Ardelyx
·
Ardelyx to Participate in Upcoming Investor Conferences
·
FY2026 Earnings Estimate for Ardelyx Issued By HC Wainwright - Defense World
·
Financial Uncertainty Surrounds Ardelyx’s Market Position
·
ARDX Q4 2025 Earnings Report on 2/19/2026
·
Press Releases | Ardelyx
·
Ardelyx, Inc. (ARDX) Stock Price, News, Quote & History - Yahoo Finance
·
Why Ardelyx (ARDX) Is Up 20.1% After Lawsuit Dismissal And Patent Extension For Tenapanor - Simply Wall St News
·
ARDX: Ardelyx Inc Latest Stock Price, Analysis, News and Trading Ideas
·
Ardelyx, Inc. Stock Price: Quote, Forecast, Splits & News (ARDX)
·
Ardelyx (ARDX) Is Down 16.3% After Issuing Higher 2026 Product Revenue Guidance and Patent Update - Simply Wall St News
·
Ardelyx (ARDX) pegs 2026 IBSRELA sales at $410-430M | ARDX Stock News
·
Ardelyx, Inc. (ARDX) Stock Price, Quote, News & Analysis | Seeking Alpha
·
Ardelyx data show rapid IBS-C relief with tenapanor | ARDX Stock News
·
Investors & Media | Ardelyx
·
Ardelyx Inc (ARDX) Growth Is Real, Panic Is Optional: What Q4 2025 Earnings Really Say | Merlintrader Trading Pub
Market & Sector Regime
Market
Bullish
0.87
-1.0
0
+1.0
Health Care Sector
Bearish
0.18
-1.0
0
+1.0
Other Patterns Detected Today
Bullish Pennant
14 days in pattern
Moderate
29.0
Post Collapse Recovery
12 days in pattern
Good
30.0
Overall Score
36
of 40
Pattern Quality
16
of 20
Setup
11
of 20
R/R
15
of 18
Context
Pattern Quality Score
13
of 15
Structure
12
of 13
Breakout
11
of 12
Volume
Recent Performance
Momentum & Trend
RSI (14)
55.5
Neutral
MACD Histogram
+0.09
Bullish
Bollinger Band Position
86.7%
Upper Zone
Volatility & Risk
20-Day Volatility
0.47
High
ATR %
4.4%
Medium
Beta
0.55
Below Mkt
Volume Analysis
Volume Ratio
1.03x
Average
20-Day Avg Vol
3.4M
shares / day
Current Volume
3.5M
shares traded
Price Levels
52W High
$8.40
Target
$6.45
Resistance
$6.28
Current
$6.18
Stop Loss
$5.87
Support
$5.11
52W Low
$3.21
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.